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OBJECTIVES: Gastro esophageal reflux disease (GERD) is commonly associated
with a significant adverse impact on the patient’s quality of life, his/her employ-
ment record, and healthcare systems. The aim of this analysis was to conduct a
pooled analysis of the data from five European studies (GERDManagement Project)
to assess the potential benefit for healthcare providers of a structured treatment
pathway (STP) for the treatment of GERD.METHODS:We conducted a meta-anal-
ysis of five cluster randomised clinical trials comparing a new management strat-
egy with usual care in patients with GERD conducted in Austria, Italy, Norway,
Spain and Sweden (NCT00842387). The educational intervention on investigators
was based on the GerdQ questionnaire to stratify adult patients with classical
symptoms of GERD according to the frequency and impact of symptoms. Themost
effective acid-suppressive therapy (esomeprazole 40 mg once daily) was proposed
to be used only in patients with the highest GerdQ symptom impact score (3 of a
possible 6). Calculations were performed using data on mean values for resource
utilization (including emergency room visits, hospitalization, primary-care physi-
cian visits, specialist visits and endoscopies) multiplied by the unit cost of each
variable. UK unit costs were applied to the entire European cohort. RESULTS: 1947
patients were included in the analysis, 944 (49%) on the STP group and 1003 (51%)
on the usual clinical practice (UCP) group. In the STP group, GerdQ scores improved
significantly more during therapy than in the UCP group. Patients in the STP group
had lower overall healthcare costs, 107.59€ per patient/year, than those in the UCP
group, 137.55€ per patient/year (i.e. 22% reduction in healthcare utilization costs).
CONCLUSIONS: The implementation of a structured treatment pathway for the
treatment of GERD based in the GerdQ questionnaire could considerably reduce
the disease healthcare utilization costs compared with the usual clinical prac-
tice.
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OBJECTIVES: Administering acid suppressive therapy, AST (proton pump inhibi-
tors, PPIs or H2 receptor antagonists, H2RAs) via enteral versus parenteral route in
Intensive Care Unit (ICU) patients for stress ulcer prophylaxis (SUP)may save costs.
As little is known on who can receive enteral vs. parenteral AST, our objective was
to evaluatewhether ICUpatients on any oralmedication orwith an oro-gastric tube
receive enteral versus parenteral AST.METHODS: In a retrospective study of elec-
tronic medical record data,  19-year-old adult patients admitted to a Midwest
AcademicMedical Center’s ICU and receiving anAST in 2008were included. Patient
data {age, gender, nonoperative/postoperative status, any oralmedication use, oro-
gastric tube, nothing by oral route (NPO), resource utilization variables (hospital
days, ICU days) and AST-use (enteral/parenteral)} were collected. Statistical differ-
ences between enteral and parenteral AST (PPI and H2RA) patient groups were
determined using Chi-square or fisher’s exact test and Wilcoxon-rank-sum tests.
In multivariate logistic regression analyses, the association of patient characteris-
tics (any oral medication use, oro-gastric tube, NPO) with enteral versus parenteral
AST-use was tested. P0.05 was considered statistically significant. RESULTS: 54%
and 43% of PPI (n392) and H2RA (n203) patients, respectively received drug
through enteral route. The enteral and parental H2RAs groups did not differ by any
characteristics. The enteral and parental PPI groups differed significantly by me-
dian hospital days (8.0 versus 13.0), median ICU days (2.0 versus 4.0), and nonop-
erative/postoperative patient-status (55%/45% versus 41%/59%). Inmultivariate lo-
gistic regression analyses, any oral medication use increased the likelihood of
enteral versus parenteral H2RA-use (P0.05) and PPI-use (P0.0001); however use
of an orogastric tube was not significantly associated. CONCLUSIONS: To realize
cost-effective quality of care, patients with an orogastric tube could receive enteral
instead of parenteral AST and further study of cost savings from such use is un-
derway.
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OBJECTIVES: This study examined comparative safety of stimulant versus atom-
oxetine with the risk of neurological adverse events in children with Attention-
Deficit/Hyperactivity Disorder (ADHD). METHODS: The IMS LifeLink Health Plan
Claims Database was used for this retrospective, propensity score matched analy-
sis of children and adolescents with ADHD on stimulant and atomoxetine. The
study sample included children less than 18 years of age initiating stimulant or
atomoxetine therapy between July 1, 2004 to December 31, 2005. Patients with
stimulant and atomoxetine were matched on propensity scores calculated based
on baseline characteristics. The neurological adverse events included tics disorder
(ICD-9-CM code-307.2x) and seizures (ICD-9-CM codes- 345.xx, 780.3, 780.39,
780.31). Conditional logistic regression was used to account for the matched pair
design. The final logistic model was adjusted for duration of therapy/persistency
alongwith other covariateswhichwere significant aftermatching. Sensitivity anal-
ysis was also performed using pharmacotherapy as themain outcomemeasure for
management of neurological adverse events. RESULTS: The propensity score
matched cohort consisted of a total of 7,424 children with ADHD (3,712-Atomox-
etine users and 3,712-Stimulant users). Conditional logistic regression revealed
that stimulant or atomoxetine use did not differ in terms of the risk of neurological
adverse events development (Odds Ratio [OR]- 0.86; 95% Confidence Interval [CI]-
0.57-1.28). However, central nervous systempathologywas significantly associated
with the development of neurological adverse events (OR-2.87; 95% CI-1.19-6.92).
Sensitivity analysis showed that stimulant use (OR-1.36; 95% CI- 1.18-1.56) was
positively associated with the treatments for neurological adverse events.
CONCLUSIONS: Stimulant use was not significantly associated with diagnosis of
neurological adverse events compared to atomoxetine in children. However, sen-
sitivity analysis revealed that the stimulant users had an increased chance of
receiving treatments for neurological adverse events. The findings suggest that
stimulant use can lead to neurological adverse events which are not documented
in ADHD patients but are usually treated.
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OBJECTIVES: To evaluate the risk of hospitalization for pneumonia associatedwith
typical and atypical antipsychotic use in an elderly Medicare population.
METHODS: This retrospective cohort study used two years (2006-2007) of 5% na-
tional sample ofMedicare claims data. Medicare beneficiarieswith continuous Part
A, B, and D enrollment in 2006-2007 and who initiated atypical or typical antipsy-
chotic drug therapy during July 2006-June 2007 were identified from Part D claims
data. Propensity score matching was used to control for potential confounding. A
conditional logistic regression model stratified on propensity score-matched pair
was used to compare the risk of hospitalization for pneumonia in new users of
atypical vs. typical antipsychotic drugs within a 180 day follow-up period starting
from the date of first prescription. RESULTS: A total of 15,637 new users of atypical
and 2,337 new users of typical antipsychotic drugs were identified July 2006-June
2007. A total of 1,363(7.6%) subjects had a hospitalization for pneumonia during
follow-up. The proportion of hospitalizations was similar in the atypical (7.5%) and
the typical antipsychotic (8.0%) groups. A total of 2,335 propensity score-matched
pairs were obtained using the Greedy 5-1 matching algorithm. In the matched
cohort, there were 186 (7.97%) pneumonia hospitalizations in typical users com-
pared to 179 (7.67%) among atypical users. Typical antipsychotics users did not
differ significantly from atypical users on the risk of pneumonia (odds ratio: 1.042,
95% CI: 0.843-1.288). Sensitivity analysis using propensity score as a continuous
variable in a multivariable logistic regression model yielded similar results (odds
ratio: 0.976, 95% CI: 0.828-1.150). CONCLUSIONS: The risk of hospitalization for
pneumonia was similar for new users of typical and atypical antipsychotic drugs.
While this indicates that there is no added safety concern for users of atypical
antipsychotics, it also suggests there is no added advantage of atypical use, espe-
cially in patients at high risk for pneumonia.
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OBJECTIVES: To study the association between the type of antipsychotic drug use
and the occurrence of hip fracture in an elderly Medicare population. METHODS:
Two years (2006-2007) of 5% national sample of Medicare claims data were used to
conduct this population-based retrospective cohort study. Medicare beneficiaries
with continuous Part A, B, and D enrollment in 2006-2007 and who initiated atyp-
ical or typical antipsychotic therapy July 2006 -June 2007 were identified from Part
D claims data. All study subjects were followed for 180 days from index date, the
date of first antipsychotic prescription. Propensity scores were calculated for each
individual using pre-index demographics, comorbidities, and medication use. Us-
ers of atypical antipsychotics and typical antipsychotics werematched on propen-
sity score using the Greedy 5-1matching algorithm. Conditional logistic regression
model stratified on propensity score-matched pair was used to compare the risk of
hospitalization for hip fracture in new users of atypical versus typical antipsy-
chotic drugs; sensitivity analysis was conducted using propensity score as a con-
tinuous, linear term in the unmatched study cohort using logistic regression.
RESULTS: 15,637 new users of atypical and 2,337 new users of typical antipsychotic
drugs were identified. 307 (1.7%) of all antipsychotic users had a hospitalization for
hip fracture during follow-up. Of these, 40were typical and 267were atypical users.
In the propensity score-matched cohort of 4,660 individuals (2,330 pairs), 40 (1.72%)
typical antipsychotic users and 38 (1.63%) atypical antipsychotic users had a hos-
pitalization for hip fracture during follow-up. The risk of hip fracturewas not found
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